Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)



Status:Active, not recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/25/2019
Start Date:March 2015
End Date:December 2019

Use our guide to learn which trials are right for you!

A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an
investigational drug called pexidartinib for the treatment of certain tumors for which
surgical removal could cause more harm than good.

The main purpose of this study is to gather information about the investigational drug
pexidartinib, which may help to treat tumors of pigmented villonodular synovitis (PVNS) or
giant cell tumor of the tendon sheath (GCT-TS).

The study consists of two parts with a follow-up period. In Part 1, eligible study
participants will be assigned to receive either pexidartinib or matching placebo for 24
weeks. A number of assessments will be carried out during the course of the study, including
physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires.
MRI scans will be used to evaluate the response of the tumors to the treatment. Some
subjects, assigned to placebo in Part 1 transitioned to pexidartinib for Part 2.

Then a protocol amendment was written to allow only pexidartinib patients to continue into
Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label
pexidartinib. There was also a follow-up period added to Part 2.


Inclusion Criteria

1. Age ≥ 18 years.

2. A diagnosis of PVNS or GCT-TS (i) that has been histologically confirmed either by a
pathologist at the treating institution or a central pathologist, and (ii) where
surgical resection would be associated with potentially worsening functional
limitation or severe morbidity (locally advanced disease), with morbidity determined
consensually by qualified personnel (eg, two surgeons or a multi-disciplinary tumor
board).

3. Measurable disease of at least 2 cm and otherwise based on RECIST 1.1, assessed from
MRI scans by a central radiologist.

4. Symptomatic disease because of active PVNS or GCT-TS, defined as one or more of the
following:

1. a worst pain of at least 4 at any time during the week preceding the Screening
Visit (based on scale of 0 to 10, with 10 representing "pain as bad as you can
imagine").

2. a worst stiffness of at least 4 at any time during the week preceding the
Screening Visit (based on a scale of 0 to 10, with 10 representing "stiffness as
bad as you can imagine").

5. Stable prescription of analgesic regimen during the 2 weeks prior to randomization.

6. During the 2 weeks prior to randomization, at least 4 of 7 consecutive days of Brief
Pain Inventory (BPI) Worst Pain NRS items and Worst Stiffness NRS items completed
correctly.

7. Women of childbearing potential must have a negative serum pregnancy test within the
14-day period prior to randomization. (Where demanded by local regulations, this test
may be required within 72 hours of randomization.)

8. Males and females of childbearing potential are permitted in the study so long as they
consent to avoid getting their partner pregnant or becoming pregnant, respectively, by
using a highly effective contraception method, as described below, throughout the
study and for up to 90 days after completion. Highly effective methods of
contraception include: intra-uterine device (nonhormonal or hormonal), bilateral tubal
occlusion, vasectomy, sexual abstinence, or barrier methods (eg, condom, diaphragm)
used in combination with hormonal methods associated with inhibition of ovulation.
Women of non-childbearing potential may be included if they are either surgically
sterile or have been postmenopausal for ≥ 1 year. Women who have documentation of at
least 12 months of spontaneous amenorrhea and have a follicle stimulating hormone
(FSH) level > 40 milli-International units (mIU/mL) will be considered postmenopausal.

9. Adequate hematologic, hepatic, and renal function, defined by:

- Absolute neutrophil count ≥ 1.5 × 109/L

- aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 1.5 × upper limit
of normal (ULN)

- Hemoglobin > 10 g/dL

- Total bilirubin ≤ 1.5 × ULN

- Platelet count ≥ 100 × 109/L

- Serum creatinine ≤ 1.5 × ULN

10. Willingness and ability to complete the Worst Pain NRS item, Worst Stiffness NRS item,
PROMIS Physical Function Scale, and other self-assessment instruments throughout the
study.

11. Willingness and ability to use an electronic diary.

12. Willingness and ability to provide written informed consent prior to any study-related
procedures and to comply with all study requirements.

Exclusion Criteria

1. Investigational drug use within 28 days of randomization.

2. Previous use of pexidartinib or any biologic treatment targeting CSF-1 or the CSF-1R;
previous use of oral tyrosine kinase inhibitors, eg, imatinib or nilotinib, are
allowed.

3. Active cancer (either concurrent or within the last year of starting study treatment)
that requires therapy (eg, surgical, chemotherapy, or radiation therapy), with the
exception of adequately treated basal or squamous cell carcinoma of the skin, melanoma
in-situ, carcinoma in-situ of the cervix or breast, or prostate carcinoma with a
prostate-specific antigen value <0.2 ng/mL.

4. Known metastatic PVNS/GCT-TS.

5. Active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus or known
active or chronic infection with human immunodeficiency virus.

6. Known active tuberculosis.

7. Significant concomitant arthropathy in the affected joint, serious illness,
uncontrolled infection, or a medical or psychiatric history that, in the
Investigator's opinion, would likely interfere with the person's study participation
or the interpretation of his or her results.

8. Women who are breastfeeding.

9. A screening Fridericia corrected QT interval (QTcF) ≥ 450 ms (men) or ≥ 470 ms
(women).

10. MRI contraindications.

11. History of hypersensitivity to any excipients in the investigational product.

12. Inability to swallow capsules.
We found this trial at
20
sites
Jacksonville, Florida 32224
Phone: 855-776-0015
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
Los Angeles, California 90033
213) 740-2311
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
3181 S.W. Sam Jackson Park Road
Portland, Oregon 97239
503 494-7999
OHSU Knight Cancer Institute OHSU Knight Cancer Institute is known worldwide for our contributions to...
?
mi
from
Portland, OR
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Phone: 855-776-0015
Mayo Clinic Cancer Center The Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah 84112
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Santa Monica, California 90404
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Scottsdale, Arizona 85259
Phone: 855-776-0015
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sydney, New South Wales
?
mi
from
Sydney,
Click here to add this to my saved trials
Tampa, Florida 33612
?
mi
from
Tampa, FL
Click here to add this to my saved trials